[The perspective fluoroplastic porous carrier for conservation and transfer of samples of blood plasma: application of "dry drop" technique with the purpose of detection of individual fatty acids.]
Aripovsky et al.
The finding, in our words
A laboratory method study showed that a fluoroplastic porous carrier for dried plasma spots quadruples sample capacity to 70-100 µl and, with antioxidant pretreatment, preserves polyunsaturated fatty acids for up to 35-40 days at room temperature or six months frozen. This enhanced stability and capacity could support decentralised collection and mailing of plasma samples for fatty acid and cholesterol analysis.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The analysis indicates that dried blood spots and volumetric absorptive microsampling enable minimally invasive monitoring of prohibited substances, with volumetric absorptive microsampling offering improved quantitative reliability over traditional dried spots.
Volumetric absorptive microsampling showed better precision than dried blood spots and a metabolic profile closer to whole blood, with stable signalling lipids for 24 hours at room temperature but significant changes after one week unless stabilised, indicating feasibility for decentralised sampling with the need for storage strategies.
Capillary dried blood spots, after haematocrit-dependent conversion, showed good agreement with plasma for 25-hydroxyvitamin D quantification, with 90 per cent of results within 20 per cent of plasma and substantial to almost perfect agreement in status classification, supporting reliable home self-collection for large-scale vitamin D monitoring.
This study validated a dried blood spot method for tacrolimus monitoring and demonstrated agreement with venous whole blood measurements in kidney transplant recipients. It also found that dried blood spot analysis of the biomarker CXCL-10 was elevated in patients experiencing rejection or infection, supporting its use for decentralised monitoring.
This review establishes that microsampling across blood, saliva, urine and stool matrices offers validated workflows and regulatory recognition for human biomonitoring comparable to conventional methods. It finds that these decentralised approaches enhance participant acceptability and enable screening in remote or low-resource settings.